Cuban vaccine against chronic hepatitis B is evaluated in eight countries
- Submitted by: Juana
- Health and Medicine
- 08 / 12 / 2015
A new Cuban vaccine against chronic hepatitis B, created by the Center for Genetic Engineering and Biotechnology (CIGB by its Spanish acronym), is currently undergoing clinical evaluation in eight countries, developed in collaboration with the French company Abivax, official media reported today.
This new product named HeberNasvac is administered nasally and subcutaneously, and has proven to be "effective and safe" when compared with other existing drugs today on the market for this virus.
HeberNasvac clinical trial involves about 230 patients and 50 clinical sites in Australia, New Zealand, Singapore, South Korea, Taiwan, Hong Kong, Philippines and Thailand.
The protocol for the evaluation of the drug has been designed by senior experts hired by Abivax, and Cuban scientists, according to sources said the CIGB, who corroborated the satisfactory progress of the trial in Asia, one of the most affected regions by the disease.
A second clinical trial of the new vaccine, still under recruitment will take place at 13 clinical sites in Cuba and will benefit 160 patients of the island.